Nora K Horick1, Ariela Muzikansky1, Hilda L Gutierrez1, Kristina L Boyd1, Dianne M Finkelstein2,3. 1. Massachusetts General Hospital Biostatistics Center, 50 Staniford St. Suite 560, Boston, MA, 02114, USA. 2. Massachusetts General Hospital Biostatistics Center, 50 Staniford St. Suite 560, Boston, MA, 02114, USA. dfinkelstein@mgh.harvard.edu. 3. Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA. dfinkelstein@mgh.harvard.edu.
Abstract
PURPOSE: Advances in cancer detection and treatment have resulted in a growing population of long-term survivors, but even years after treatment has concluded, many survivors report physical symptoms that interfere with daily living. While there are studies of late effects following common cancers, less is known about these complications in rare cancers. This study focuses on the physical symptoms reported by long-term survivors enrolled in the NIH-sponsored Rare Cancer Genetics Registry. METHODS: The Rotterdam Symptom Checklist-Modified was administered to evaluate the severity of physical symptoms commonly reported by long-term cancer survivors. Logistic regression was used to assess association between symptoms and demographic and clinical factors. RESULTS: In 309 subjects with a median time of 7.6 years from a diagnosis of one or more rare cancers, the median number of symptoms present per participant was 7. The most prevalent symptom reported was tiredness/lack of energy, which was present/very bothersome in 70%/25% of registrants. Women, non-whites, current smokers, and upper GI cancer survivors are particularly affected. Overall, symptom prevalence was similar across rare cancer types, time since diagnosis, and type of treatment. CONCLUSIONS: Rare cancer survivors continue to experience troublesome symptoms many years after diagnosis, regardless of cancer type or treatment modality. IMPLICATIONS FOR CANCER SURVIVORS: There is a need for continued emphasis on smoking cessation in cancer survivors as well as enhanced monitoring of long-term complications in female, non-white, and upper GI cancer survivors.
PURPOSE: Advances in cancer detection and treatment have resulted in a growing population of long-term survivors, but even years after treatment has concluded, many survivors report physical symptoms that interfere with daily living. While there are studies of late effects following common cancers, less is known about these complications in rare cancers. This study focuses on the physical symptoms reported by long-term survivors enrolled in the NIH-sponsored Rare Cancer Genetics Registry. METHODS: The Rotterdam Symptom Checklist-Modified was administered to evaluate the severity of physical symptoms commonly reported by long-term cancer survivors. Logistic regression was used to assess association between symptoms and demographic and clinical factors. RESULTS: In 309 subjects with a median time of 7.6 years from a diagnosis of one or more rare cancers, the median number of symptoms present per participant was 7. The most prevalent symptom reported was tiredness/lack of energy, which was present/very bothersome in 70%/25% of registrants. Women, non-whites, current smokers, and upper GI cancer survivors are particularly affected. Overall, symptom prevalence was similar across rare cancer types, time since diagnosis, and type of treatment. CONCLUSIONS: Rare cancer survivors continue to experience troublesome symptoms many years after diagnosis, regardless of cancer type or treatment modality. IMPLICATIONS FOR CANCER SURVIVORS: There is a need for continued emphasis on smoking cessation in cancer survivors as well as enhanced monitoring of long-term complications in female, non-white, and upper GI cancer survivors.
Authors: Im-Ryung Kim; Soo Hyun Kim; Oh Nam Ok; So Hee Kim; Suyeon Lee; Eunju Choi; Seok Jin Kim; Dok Hyun Yoon; Moon Hee Lee Journal: Ann Hematol Date: 2017-02-09 Impact factor: 3.673
Authors: Ping Yang; Andrea L Cheville; Jason A Wampfler; Yolanda I Garces; Aminah Jatoi; Matthew M Clark; Stephen D Cassivi; David E Midthun; Randolph S Marks; Marie-Christine Aubry; Scott H Okuno; Brent A Williams; Francis C Nichols; Victor F Trastek; Hiroshi Sugimura; Linda Sarna; Mark S Allen; Claude Deschamps; Jeff A Sloan Journal: J Thorac Oncol Date: 2012-01 Impact factor: 15.609
Authors: Joseph W Ditre; Brian D Gonzalez; Vani N Simmons; Leigh Anne Faul; Thomas H Brandon; Paul B Jacobsen Journal: Pain Date: 2011-01 Impact factor: 6.961
Authors: Lawrence H Kushi; Colleen Doyle; Marji McCullough; Cheryl L Rock; Wendy Demark-Wahnefried; Elisa V Bandera; Susan Gapstur; Alpa V Patel; Kimberly Andrews; Ted Gansler Journal: CA Cancer J Clin Date: 2012 Jan-Feb Impact factor: 508.702
Authors: G Bouras; S R Markar; E M Burns; J R Huddy; A Bottle; T Athanasiou; A Darzi; G B Hanna Journal: Eur J Surg Oncol Date: 2016-11-09 Impact factor: 4.424
Authors: Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Allison J Applebaum; Laura C Polacek; Leah Walsh; Anne S Reiner; Kathleen Lynch; Stephanie Benvengo; Justin Buthorn; Thomas M Atkinson; Jun J Mao; Katherine S Panageas; Eli L Diamond Journal: Leuk Lymphoma Date: 2020-02-24